Andrew Schwendenman Sells 2,298 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CAO Andrew Schwendenman sold 2,298 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $14,868.06. Following the completion of the transaction, the chief accounting officer now directly owns 38,238 shares of the company’s stock, valued at $247,399.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $5.57 on Wednesday. Replimune Group, Inc. has a 12 month low of $5.47 and a 12 month high of $24.81. The company has a current ratio of 10.72, a quick ratio of 10.72 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $342.11 million, a PE ratio of -1.72 and a beta of 1.25. The stock’s fifty day simple moving average is $7.16 and its 200 day simple moving average is $8.19.

Institutional Trading of Replimune Group

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in Replimune Group by 236.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after acquiring an additional 2,958 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 352.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,833 shares of the company’s stock valued at $58,000 after purchasing an additional 5,324 shares during the period. Exchange Traded Concepts LLC lifted its stake in shares of Replimune Group by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock worth $66,000 after buying an additional 1,988 shares during the last quarter. Quest Partners LLC acquired a new position in Replimune Group in the 4th quarter valued at about $76,000. Finally, Diversified Trust Co bought a new position in Replimune Group in the 1st quarter valued at about $94,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.